Cartesian Therapeutics, Inc. revenue breakdown overview

Cartesian Therapeutics, Inc. revenue for the last year amounted to 26.00 M USD, the most of which — 26.00 M USD — came from its highest performing source at the moment, Nanoparticle Immunomodulatory Drugs, the year earlier bringing 110.78 M USD. The greatest contribution to the revenue figure was made by United States — last year it brought Cartesian Therapeutics, Inc. 26.00 M USD, and the year before that — 110.78 M USD.